¼¼°èÀÇ miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå
miRNA Sequencing and Assays
»óǰÄÚµå : 1661925
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 465 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀåÀº 2030³â±îÁö 7¾ï 6,310¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 3¾ï 7,900¸¸ ´Þ·¯·Î ÃßÁ¤µÈ miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀåÀº 2030³â¿¡´Â 7¾ï 6,310¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGRÀº 12.4%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ miRNA ½ÃÄö½Ì£¦¾î¼¼ÀÌ Á¦Ç°Àº CAGR 11.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 350¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. miRNA ½ÃÄö½Ì£¦¾î¼¼ÀÌ ¼­ºñ½º ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 14.3%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 330¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 16.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀåÀº 2024³â¿¡ 1¾ï 330¸¸ ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 5,950¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGRÀº 16.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 9.1%¿Í 11.0%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 9.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö miRNA ½ÃÄö½ÌÀÌ »ý¹°ÀÇÇÐ ¿¬±¸¿¡¼­ Àü·Ê ¾ø´Â ÁÖ¸ñÀ» ¹Þ´Â°¡?

¸¶ÀÌÅ©·ÎRNA(miRNA) ½ÃÄö½ÌÀº ´Ù¾çÇÑ Áúº´¿¡¼­ À¯ÀüÀÚ Á¶Àý°ú ±× Àǹ̸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¾Ï, ½Å°æ ÅðÇ༺ Áúȯ, ½ÉÇ÷°ü Áúȯ°ú °°Àº º¹ÀâÇÑ Áúº´ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¬±¸ÀÚµéÀº ¹ÙÀÌ¿À¸¶Ä¿¿Í Ä¡·á Ç¥ÀûÀ» È®ÀÎÇϱâ À§ÇØ miRNA ÇÁ·ÎÆÄÀϸµ¿¡ Á¡Á¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ¹ßÇöÀ» Á¶ÀýÇÏ°í ¼¼Æ÷ °úÁ¤¿¡ °ü¿©ÇÏ´Â miRNAÀÇ ´É·ÂÀº Á¤¹ÐÀÇ·á¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. À¯ÀüüÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Â÷¼¼´ë ½ÃÄö½Ì(NGS) ±â¼úÀÇ ¹ßÀüÀº miRNA ½ÃÄö¼­ÀÇ Ã¤Åÿ¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°úÇÐ ¿¬±¸¿¡ ÀÚ±ÝÀ» Áö¿øÇÏ´Â °ø°ø ¹× ¹Î°£ ÀÌ´Ï¼ÅÆ¼ºê´Â ÃÖ÷´Ü miRNA ºÐ¼® ±â¼ú °³¹ßÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °Íµµ miRNA ½ÃÄö½ÌÀÌ °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ÇÊ¿äÇÑ Á¤È®¼º°ú ƯÀ̼ºÀ» Á¦°øÇÑ´Ù´Â Á¡¿¡¼­ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº miRNA ºÐ¼® ½ÃÀå¿¡ ¾î¶² Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í Àִ°¡?

miRNA ºÐ¼® ½ÃÀåÀº ½ÃÄö½Ì Ç÷§Æû°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ÅøÀÇ Çõ½Å¿¡ ÈûÀÔ¾î ±â¼úÀû º¯Çõ±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ´ÜÀÏ ¼¼Æ÷ RNA ½ÃÄö½Ì°ú °°Àº ÷´Ü ½ÃÄö½Ì ±â¼úÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº miRNAÀÇ ¹ßÇö°ú Áúº´ °æ·Î¿¡¼­ miRNAÀÇ ¿ªÇÒ¿¡ ´ëÇÑ º¸´Ù »ó¼¼ÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, µ¥ÀÌÅÍ ºÐ¼®¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© º¹ÀâÇÑ miRNA µ¥ÀÌÅÍ ¼¼Æ®ÀÇ ÇØ¼®À» °£¼ÒÈ­ÇÏ¿© ¿¬±¸ÀÚ¿Í ÀÓ»óÀǰ¡ º¸´Ù ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ´õ ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Æ÷ÇÔÇÑ ºÐ¼® ŰƮÀÇ Çõ½ÅÀº miRNA °ËÃâÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ miRNA¸¦ µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º ºÐ¼®¹ýÀÇ °³¹ß·Î ´ë±Ô¸ð ¿¬±¸¿¡ ¼Ò¿äµÇ´Â ºñ¿ë°ú ½Ã°£À» Å©°Ô Àý°¨ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº miRNA ºÐ¼®ÀÇ Àü¹ÝÀûÀÎ È¿À²¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó Áø´Ü, ½Å¾à°³¹ß, Ä¡·áÁ¦ °³¹ßÀÇ ÀÀ¿ë °¡´É¼ºÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù.

½ÃÀå È®´ë¿¡ ÀÖ¾î ÇコÄÉ¾î ¿ëµµÀÇ ¿ªÇÒÀº?

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ miRNA ½ÃÄö½ÌÀÇ Àû¿ëÀº ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Á¾¾çÇп¡¼­ miRNA ÇÁ·ÎÆÄÀϸµÀº ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇϰí, ȯÀÚÀÇ ¿¹Èĸ¦ ¿¹ÃøÇϰí, Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â Áø´Ü °Ë»ç °³¹ß¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ½Å°æÇп¡¼­´Â ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´ ¹× ±âŸ ½Å°æ ÅðÇ༺ ÁúȯÀÇ ¹ÙÀÌ¿À¸¶Ä¿·Î miRNA°¡ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. Áø´ÜÇÐ ¿Ü¿¡µµ, miRNA ºÐ¼®Àº Ä¡·áÇп¡¼­µµ ÁÖ¸ñÀ» ¹Þ°í ÀÖÀ¸¸ç, ¸¹Àº ÀÓ»ó½ÃÇè¿¡¼­ Ç¥Àû Ä¡·á¿¡ÀÇ È°¿ëÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. »êÀü ¼±º°°Ë»ç, °¨¿° Áø´Ü, ¸é¿ª ¹ÝÀÀ ¸ð´ÏÅ͸µ¿¡ miRNA ½ÃÄö½ÌÀ» ÅëÇÕÇÏ´Â °ÍÀº ±× ´ÙÀç´Ù´ÉÇÔÀ» ´õ¿í ÀÔÁõÇϰí ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¶±â ¹ß°ß ¹× Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½ÉÀº ÇコÄÉ¾î ºÐ¾ß¿¡¼­ miRNA ½ÃÄö½Ì ¹× ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â »ý¹° ÀÇÇÐ ¿¬±¸ ¹× ÇコÄɾîÀÇ ¹ßÀü¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¾Ï ¹× ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ miRNA ±â¹Ý Áø´Ü ¹× Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, NGS ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ miRNA ½ÃÄö½ÌÀÌ ´õ¿í Á¤È®ÇÏ°í ºñ¿ë È¿À²ÀûÀÌ¸ç ³Î¸® »ç¿ë °¡´ÉÇØÁ® ½ÃÀå È®»ê¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ½Å¾à °³¹ß ÆÄÀÌÇÁ¶óÀο¡¼­ miRNA ÇÁ·ÎÆÄÀϸµÀÇ ÅëÇÕÀÌ Áõ°¡ÇÏ´Â °Íµµ ÁÖ¿ä ±â¿© ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀû ¾×ü »ý°Ë¿¡¼­ miRNAÀÇ Àû¿ëÀÌ È®´ëµÇ°í Áúº´ ¸ÞÄ¿´ÏÁòÀ» ±Ô¸íÇÏ´Â µ¥ ÀÖ¾î miRNAÀÇ ¿ªÇÒÀÌ È®´ëµÇ¸é¼­ Çö´ë ÀÇÇп¡¼­ miRNAÀÇ °ü·Ã¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀεéÀÌ °áÇÕÇÏ¿© ½ÃÀå »óȲÀº °ßÁ¶ÇÑ ¼ºÀåÀ» ÇâÇØ ³ª¾Æ°¡°í ÀÖÀ¸¸ç, À¯Àüü ¿¬±¸¿Í ÀÓ»ó Àü¸ÁÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° ¹× ¼­ºñ½º(miRNA ½ÃÄö½Ì ¹× ºÐ¼® Á¦Ç°, miRNA ½ÃÄö½Ì ¹× ºÐ¼® ¼­ºñ½º), ±â¼ú(ÇÕ¼º±â¼ú¿¡ ÀÇÇÑ ½ÃÄö½Ì, ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå µå¶óÀ̰ÔÀÌ¼Ç ¹× °ËÃâ(SOLiD) ±â¼ú¿¡ ÀÇÇÑ ½ÃÄö½Ì, ³ª³ëÆ÷¾î ½ÃÄö½Ì ±â¼ú, ½Ì¾î ½ÃÄö½Ì ±â¼ú, ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£(SMRT) ½ÃÄö½Ì ±â¼ú), ¿ëµµ(¾Ï ¿ëµµ, Æú¸®±Û·çŸ¹Î Áúȯ ¿ëµµ, ÀÚ°¡¸é¿ªÁúȯ ¿ëµµ, Á¶Çöº´ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(¿¬±¸/Çмú±â°ü ÃÖÁ¾ ¿ëµµ, Á¦¾à/¹ÙÀÌ¿À ±â¾÷ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¿ä 27°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global miRNA Sequencing and Assays Market to Reach US$763.1 Million by 2030

The global market for miRNA Sequencing and Assays estimated at US$379.0 Million in the year 2024, is expected to reach US$763.1 Million by 2030, growing at a CAGR of 12.4% over the analysis period 2024-2030. miRNA Sequencing & Assay Products, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$603.5 Million by the end of the analysis period. Growth in the miRNA Sequencing & Assay Services segment is estimated at 14.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$103.3 Million While China is Forecast to Grow at 16.5% CAGR

The miRNA Sequencing and Assays market in the U.S. is estimated at US$103.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$159.5 Million by the year 2030 trailing a CAGR of 16.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Global miRNA Sequencing and Assays Market - Key Trends & Drivers Summarized

Why Is miRNA Sequencing Gaining Unprecedented Attention in Biomedical Research?

MicroRNA (miRNA) sequencing has emerged as a critical tool in understanding gene regulation and its implications in various diseases. With the rise in complex diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions, researchers are increasingly turning to miRNA profiling to identify biomarkers and therapeutic targets. The ability of miRNAs to regulate gene expression and play a role in cellular processes makes them invaluable in precision medicine. The growing investment in genomics and advancements in next-generation sequencing (NGS) technologies have further fueled the adoption of miRNA sequencing. Moreover, public and private initiatives to fund life sciences research are accelerating the development of cutting-edge miRNA assay technologies. The increasing interest in personalized medicine is also contributing to the demand, as miRNA sequencing provides the precision and specificity required to tailor treatments.

How Are Technological Advancements Revolutionizing the miRNA Assays Market?

The miRNA assays market is undergoing a technological transformation, driven by innovations in sequencing platforms and bioinformatics tools. Advanced sequencing technologies, such as single-cell RNA sequencing, are enabling researchers to obtain more detailed insights into miRNA expression and its role in disease pathways. Additionally, the integration of artificial intelligence and machine learning in data analysis has simplified the interpretation of complex miRNA datasets, making the technology more accessible to researchers and clinicians. Innovations in assay kits, including higher sensitivity and specificity, have enhanced the reliability of miRNA detection. Furthermore, the development of multiplexed assays that can simultaneously analyze multiple miRNAs has significantly reduced the cost and time associated with large-scale studies. These advancements not only improve the overall efficiency of miRNA analysis but also broaden its applicability in diagnostics, drug discovery, and therapeutic development.

What Role Do Healthcare Applications Play in Expanding the Market?

The application of miRNA sequencing in healthcare is a major driver of its market expansion. In oncology, for instance, miRNA profiling is being used to develop diagnostic tests that can detect cancer at an early stage, predict patient outcomes, and monitor disease progression. Similarly, in neurology, miRNAs are being investigated as biomarkers for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. In addition to diagnostics, miRNA assays are gaining traction in therapeutics, with numerous clinical trials exploring their use in targeted treatments. The integration of miRNA sequencing in prenatal screening, infectious disease diagnostics, and immune response monitoring further demonstrates its versatility. The increasing prevalence of chronic diseases and the global focus on early detection and precision medicine are expected to sustain the demand for miRNA sequencing and assays in the healthcare sector.

What Is Driving Growth in the miRNA Sequencing and Assays Market?

The growth in the miRNA sequencing and assays market is driven by several factors that underscore its pivotal role in advancing biomedical research and healthcare. The rising prevalence of cancer and chronic diseases has significantly increased the demand for miRNA-based diagnostics and therapeutics. Advancements in NGS technologies have made miRNA sequencing more accurate, cost-effective, and widely accessible, further fueling market adoption. The growing focus on personalized medicine and the increasing integration of miRNA profiling in drug discovery pipelines are also key contributors. Moreover, the expanding application of miRNAs in non-invasive liquid biopsies and their role in understanding disease mechanisms have boosted their relevance in modern medicine. Together, these drivers are propelling the miRNA sequencing and assays market toward robust growth, reshaping the landscape of genomic research and clinical practice.

SCOPE OF STUDY:

The report analyzes the miRNA Sequencing and Assays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (miRNA Sequencing & Assay Products, miRNA Sequencing & Assay Services); Technology (Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology, Single Molecule Real-time (SMRT) Sequencing Technology); Application (Cancer Application, Polyglutamine Diseases Application, Autoimmune Diseases Application, Schizophrenia Application, Other Applications); End-Use (Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 27 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â